Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialW. Timothy Garvey, Anuj Bhargava, Naveed Sattar et al.|The Lancet|2023Cited by 676
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimensJuan P. Frías, Deborah A. Robins|Diabetes Obesity and Metabolism|2020Cited by 204